Bio-Rad Laboratories (BIO) Q3 2026 earnings review
Bio-Rad sales stop falling, but restructuring charges erase reported profit
Bio-Rad, a maker of hospital diagnostic tests and lab research equipment, returned to constant-currency sales growth while booking heavy restructuring charges. Sales at constant currency edged up 1% to $656 million as hospital testing and digital genetic-testing machines outweighed a drop in drug-purification resins. Chief executive Norman Schwartz held the full-year outlook unchanged, and operating margin excluding one-offs rose 1 percentage point to 12.8% after the company cut research spending.
| Sales at constant currency | +0.7% -1.9% last quarter |
|---|---|
| Operating margin, excluding one-offs | 12.8% +1.0 percentage point from a year ago |
| Profit per share, excluding one-offs | $2.65 +17% from a year ago |
| Full-year 2026 outlook | Unchanged middle of the range: -1.25% sales |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because the margin gain came from cutting research projects that also triggered another $50 million technology write-off, while selling and administrative overhead still outpaced sales. One caution: keeping the Life Science full-year plan requires the research unit to swing from a 2.4% drop this quarter to 3.3% growth in the fourth quarter by our math.
The question now is whether the three-quarter jump in digital PCR machine placements turns into recurring chemical-kit sales and lifts the wider lab unit. If kit orders follow and drug-purification orders steady, Life Science hits its fourth-quarter ramp; if university and biotech budgets stay tight, the unit misses its full-year target. Fourth-quarter segment sales and management's first 2027 margin outlook will settle it.
🐂 Bull Case
Hospital Testing and Digital PCR Lifted Sales
Bio-Rad sells equipment and chemical kits to two groups: hospital labs and research scientists. Chief executive Norman Schwartz said: "We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™ PCR instruments." Droplet Digital PCR (ddPCR) is a tool that counts genetic material by splitting a sample into thousands of tiny drops.
- Total sales at constant currency: up 0.7% from a year ago, after falling 1.9% last quarter
- Clinical Diagnostics (hospital testing, 61% of sales): up 2.8% at constant currency on "growth in quality systems and diabetes products"
- ddPCR product line: up 7% at constant currency, with instrument sales up more than 20%
- Life Science without process chromatography: up 2.5% at constant currency
The return to growth matters because it passed an important anniversary. Bio-Rad bought digital PCR rival Stilla Technologies at the end of June last year, so this quarter's 7% ddPCR growth came from businesses it owned a year ago. The California group also launched its ChemiDoc Pro imaging system and new pre-packed filter columns.
What to watch: whether customers buy more chemical kits to run on those new ddPCR machines on the conference call. Instrument sales have grown above 20% for three quarters, and management has said kit sales usually follow 6 to 12 months later.
Research Cuts Lifted the Operating Margin
Operating profit excluding one-offs rose 8.7% from a year ago to $83.7 million, lifting the operating margin by 1.0 percentage point to 12.8%. That beat the 12.2% second-half pace implied by the middle of the full-year plan by our math. Schwartz credited the company's restructuring work and said Bio-Rad is reshaped around fewer research projects.
Two cost lines drove the gain while overhead moved the other way. The cost of making products fell 1.0 percentage point of sales, lifting gross margin excluding one-offs to 54.5%. Research and development spending excluding one-offs fell 1.6 points of sales to $60.0 million, but selling and administrative overhead rose 1.7 points to $214.1 million.
The company is also working with activist investor Elliott Management on cost and value plans, and booked $77.2 million of restructuring charges this quarter for its July layoff and facility-closure programme. Management has said those cuts will save $30 million to $35 million a year by the end of 2027.
What to watch: the 2027 operating margin target when Bio-Rad reports fourth-quarter results. A target that expands by at least 0.4 percentage points would show the new cost cuts are reaching the bottom line instead of covering rising overhead.
🐻 Bear Case
Research Cuts Brought Another Technology Write-Off
Schwartz said: "The reprioritization of our R&D efforts is yielding new, differentiated products for our customers, and our progress gives us confidence in our 2026 outlook." The presentation tells a harder story about that research shift: Bio-Rad took a $49.8 million charge for the "discontinuation and reprioritization of certain R&D programs".
That write-off means technology the life-science group bought in past acquisitions is no longer worth what it paid. It follows a $172.8 million write-off for cancelled research programmes just three quarters ago. Together with $77.2 million in restructuring charges for layoffs and plant closures, one-off charges pushed reported operations into a $49.7 million loss.
This matters because the 1.0-point gain in operating margin excluding one-offs came from cutting research spending while selling and administrative costs grew faster than sales. Repeated restructuring waves and cancelled projects have still left the full-year operating margin target at 10% to 12%, down from 12.9% in 2024.
What to watch: selling and administrative spending as a share of sales in the fourth quarter. If overhead stays above 32% of sales, the restructuring savings are paying for general cost inflation rather than lifting profit.
Plan Still Needs a Fourth-Quarter Lab Recovery
Bio-Rad's Life Science unit sells instruments and materials to universities and drug makers. Sales in the unit fell 2.4% at constant currency to $254.6 million, which the company blamed on "lower process chromatography sales and ongoing challenges in the academic research market". Process chromatography uses resins to purify biological drugs during manufacturing.
Without process chromatography, Life Science sales grew 2.5% at constant currency, up from a 0.3% drop last quarter. That shows drug-purification orders — which are concentrated among vaccine makers — were the main drag. Sales fell in the Americas, where university labs face tight government budgets, while Europe and Asia grew.
Even so, Bio-Rad kept its full-year Life Science target at a 1.0% to 3.0% constant-currency drop. Because the unit is down 3.9% through nine months, hitting the -2.0% middle of that range requires 3.3% growth in the fourth quarter by our math — a 5.7-point jump from this quarter.
What to watch: fourth-quarter Life Science constant-currency growth against the implied +1.0% to +5.7% range. A result below zero would leave the segment short of its full-year target even after the spring cut.
Buybacks Stopped While Sartorius Swung Reported Profit
Bio-Rad owns a large stake in German lab-equipment maker Sartorius AG, worth $5.85 billion at quarter-end. Accounting rules force the company to record swings in Sartorius's market value inside reported net income. A $588.2 million paper gain produced $458.6 million in reported profit this quarter, after a $341.9 million loss a year ago.
Alongside that paper gain, Bio-Rad bought back no shares in the third quarter: nine-month buybacks stayed at $79.3 million, identical to the six-month figure and down from $295.5 million a year ago. The balance sheet also carries $400.9 million of debt due within a year against $1.66 billion in cash and short-term investments.
What to watch: whether management uses cash to pay off the $400 million bond due in March 2027 or refinances it at a higher interest rate, and whether any plan for the Sartorius stake emerges.
Risks this quarter didn't answer
The press release and slides gave no new numbers on three standing operational concerns that usually wait for the conference call or quarterly filing.
- Digital PCR chemical kit sales: slides reported 7% total ddPCR growth and 20%+ instrument growth, but did not say whether consumable kit sales stopped falling.
- China hospital and research demand: slides noted Asia-Pacific grew in both units, without updating last quarter's high-teens drop in China.
- Middle East shipping and restocking: Europe, Middle East and Africa hospital testing sales fell, with no breakdown of Middle East orders or freight costs.
💲 Other KPIs
Free cash flow — operating cash after factory equipment spending — fell 26.9% from a year ago, as cash paid to suppliers and staff rose across the first nine months and restructuring began. Nine-month free cash flow is $210.0 million, down 17.8% from $255.5 million last year.
Unsold goods on the balance sheet rose again, up $3.3 million from June and $43.2 million (5.8%) since December 2025, while nine-month sales rose only 0.5%. The build in unsold stock and other working capital took $35.0 million of cash over the first nine months.
🔮 Guidance
Unchanged. The full-year plan still calls for sales at constant currency between a 3.0% drop and 0.5% growth, with the middle at -1.25%. Because nine-month sales are down 1.7% at constant currency, the middle of the plan leaves fourth-quarter sales roughly flat (-0.02%) by our math. Bio-Rad cut this range in the first quarter and has held it for two quarters.
Unchanged. Management still expects the lab-research unit's constant-currency sales to fall between 1.0% and 3.0% this year. After a 3.9% drop through nine months, hitting the -2.0% middle of the range requires 3.3% growth in the fourth quarter by our math — and even the -3.0% bottom requires growth of 1.0%.
Unchanged. The hospital-testing outlook stays at a 3.0% drop to 1.0% growth at constant currency. Because the unit is down only 0.3% through nine months and grew 2.8% this quarter, the -1.0% middle of the range allows for a 2.9% fourth-quarter drop against last year's high 5.6% base by our math.
Unchanged. The full-year target stays at 53.0% to 54.0%. Nine-month gross margin excluding one-offs is 53.9% after reaching 54.5% this quarter, so the 53.5% middle of the full-year range leaves 52.4% for the fourth quarter by our math, down from this quarter as lower-margin instrument shipments typically rise at year-end.
Unchanged. The full-year operating margin plan remains 10.0% to 12.0%, excluding 0.83 percentage points of intangible amortization. Nine-month margin is 10.7%, so the 11.0% middle of the range points to 11.8% in the fourth quarter by our math, down 1.0 point from this quarter's 12.8%.
Unchanged. The full-year cash plan stays at $290 million to $340 million. With $210.0 million collected in the first nine months, the $315 million middle of the range leaves $105 million for the fourth quarter by our math — up from $65.2 million this quarter, but 11.8% below last year's fourth quarter as cash severance payments take effect.
❓ Key Questions
Did digital PCR chemical kit sales return to growth?
Instrument sales have grown more than 20% for three straight quarters, and management said consumable kit sales follow by 6 to 12 months. The release gave total ddPCR growth of 7% but did not say whether kit sales stopped falling.
How much did process chromatography fall this quarter?
Life Science sales fell 2.4% at constant currency in total, but rose 2.5% without process chromatography. Knowing the exact drop in drug-purification resins will show how much fourth-quarter recovery is needed to hit the segment plan.
Why did Bio-Rad stop buying back shares in Q3?
Nine-month share buybacks stayed at $79.3 million, meaning zero purchases in the third quarter despite $1.66 billion in cash and short-term investments. Investors need to know whether cash is being held for the $400.9 million debt due in March 2027.
Which cancelled research projects caused the $50 million write-off?
Bio-Rad wrote off $49.8 million of acquired intangible assets after cancelling research programmes, following a $172.8 million write-off in late 2025. Naming the affected acquisitions will show which past deals failed to pay off.